logo.jpg
Vallon Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update
November 12, 2021 08:05 ET | Vallon Pharmaceuticals Inc.
- Ongoing pivotal intranasal abuse study of lead program, ADAIR, advancing toward completion of patient enrollment and treatment in Q1 2022 - Advancement of second development program, ADMIR, with...
logo.jpg
Vallon Pharmaceuticals Provides Update on Recent Pipeline and Corporate Advancements
October 12, 2021 08:35 ET | Vallon Pharmaceuticals Inc.
- Lead program, ADAIR, advancing toward completion of patient enrollment and treatment in ongoing SEAL study - Selection of final formulation completed for second development program, ADMIR ...
logo.jpg
Vallon Pharmaceuticals Continues Advancement of Pivotal Study in Lead Development Program, ADAIR, Toward Potential Approval
April 13, 2021 08:05 ET | Vallon Pharmaceuticals Inc.
- Ongoing ADAIR SEAL study on target for pivotal data readout in second half of 2021- Target NDA filing in Q2 2022 for a potential abuse-deterrent alternative to commercially available IR amphetamines...